1 March 1969 Bronchial Asthma-Robertson et al. BRITISH in average P.E.F. rates in the morning or in the evening. All patients who were symptomatically better had an increase in P.E.F., including the three patients who had a smaller F.E.V.1; the use of a peak flow meter is of considerable value in following the response to treatment in asthmatics over a period of days or weeks, and in this trial it provided useful confirmation of symptomatic benefit (Epstein et al., 1969) . The degree of symptomatic improvement did not correlate with initial F.E.V.1 results. Moran et al. (1968) reported a greater improvement in the younger patients, but in our series the reverse obtained.
In the nine patients there was a reduction in average values of F.R.C. and R.V. Woolcock and Read (1966) found a greater reduction in T.L.C. in many of their cases, whereas only one of our patients showed a fall of as much as 1 litre. The difference may be due to the fact that Woolcock and Read's patients were studied during and after severe status asthmaticus.
We did not find any improvement in exercise capacity in those who were symptomatically better despite an increase in ventilatory capacity as judged by F.E.V.1 and specific conductance of airways. It would seem that ventilation did not limit exercise capacity in our subjects, though it would be expected to do so with a greater degree of airway obstruction. The reduction in pulse rate is unexplained.
Altounyan (1964) showed that during attacks of asthma associated with allergy there is a poor response to inhaled atropine methylnitrate compared with isoprenaline sulphate, but that treatment with corticosteroids increases the atropine response. Patients with non-allergic airway obstruction usually have a high atropine response. In the present study the six asthmatics having steroids had a much greater atropine response than those not having steroids. Furthermore, those not having steroids had an increase in atropine response after treatment with disodium cromoglycate. If a poor atropine response indicates an allergic basis for increased airway resistance, both steroids and disodium cromoglycate appear to interrupt this allergic process, not necessarily by the same mechanism. Pepys et al. (1968) showed that previous inhalation of disodium cromoglycate inhibited allergic reactions produced by inhalation of appropriate allergens in asthmatic patients.
We included sensitive tests of airway resistance and lung volumes, using the body plethysmograph, and of exercise performance in our study because we thought that these methods might show a physiological basis for subjective improvement in the absence of improvement in F.E.V.1. In fact these more elaborate techniques proved less useful than the simple daily measurement of P.E.F. It seems that Howell and Altounyan's (1967) failure to show objective improvement in patients whose symptoms were diminished by disodium cromoglycate was due to the unreliability of isolated measurements in asthmatic patients. The value of daily measurements of P.E.F. recommended by Epstein et al. (1969) is confirmed by this study. Grant (1968) criticized claims that have been made of benefit from disodium cromoglycate on the ground that the degree of improvement obtained has been too small to be worth while in most cases. It can be seen from our results that there was a very marked symptomatic improvement in the nine patients who were benefited and that they showed on average a 30 % improvement in P.E.F. rate accompanied by a 65% improvement in specific conductance. These changes appear to us to be well worth while.
INTRODUCTION
Oral contraception with conventional oestrogen-progesterone combinations produces significant rises in specific bloodclotting factors-that is, factors VII and X (Thomson and Poller, 1965) . The rise becomes significant from the third Preliminary Communications month onwards (Poller and Thomson, 1966) , and is not diminished by using low-dose preparations (Poller et al., 1968) .
In the present trial a pure progesterone preparation, chlormadinone acetate, was studied in a group of women volunteers. The results with this progesterone preparation are in such sharp contrast to those we have reported previously that we are presenting our preliminary findings at the three-month stage.
METHOD OF STUDY
The women in this investigation volunteered following a public appeal for participants in a trial of progesterone oral contraception. The hormone used was chlormadinone acetate, which was given continually in a daily dosage of 0 5 mg. Investigations were performed before starting and subsequently at monthly intervals.
, The women in this progesterone study totalled 76 and *ere divided into two groups. The first were those taking an oral contraceptive for the first time and the second group were those already taking some conventional combined or sequential preparation. A normal group consisted of an equal number of women not taking the "pill," but of a similar age group, and included women in group 1 before they started to take chlormadinone. The normals were tested in parallel. The normals and the volunteers for the study were'asked to attend the department between 9 and 10 a.m., and a venous blood sample was collected. All subjects were made to rest for at least five minutes before venepuncture.
Technique.-The methods for measuring the one-stage prothrombin time, the cephalin time, the kaolin-activated cephalin time, and the factor VII and factor X assays were as described previously (Thomson and Poller, 1965; Poller and Thomson, 1966) . These tests were carried out on every sample in the progesterone study and the controls. In group 1 only the following additional tests were performed: fibrinogen (Ratnoff and Menzie, 1951) in 20 women; the dilute whole blood clot lysis time (Fearnley et al., 1957, modified) in all cases; thromboelastography (Hartert) in 10 women; and platelet aggregation by Chandler's tube and an adenosinediphosphate-induced optical density method in 18 women.
RESULTS
Of the 40 women in group 1 who had not previously taken oral contraceptives, 37 kept all their appointments up to the three-month stage. Of the 36 in the second group who had changed to chlormadinone, 23 made their four visits. Those women who did not keep their four appointments were excluded from the study. There has been no fall-out because of pregnancy.
The women in the group not having taken oral contraceptives previously showed no statistically significant change in any of the clotting-tests or specific coagulation assays over the first three cycles. Results for dilute whole blood clot lysis times, which was modified by using a 1/20 dilution, are given in the tion studies showed no significant change with either coagulation-induced (Chandler's tube) or adenosine-diphosphateinduced methods. The second group of women had been taking some conventional oestrogen-progesterone combination for an average of 14 months. There was a significant shortening of the prothrombin time and significantly raised levels of factor VII and factor X before starting chlormadinone. Cephalin times were not shortened. The results of factor VII and X assays over the three months of chlormadinone administration are shown in Fig. 1 . By the second month the prothrombin time had returned to the normal range and by the third month the factor VII level was no longer significantly increased. The factor X level, though falling, was still significantly high. 
DISCUSSION
There is clinical evidence that oestrogens promote haemostasis, and they have been used for some time as haemostatic agents in certain clinical states (Blackburn, 1963; Berkarda et al., 1965) . There is also believed to be an increased thrombotic tendency in women whose lactation is suppressed by oestrogens (Daniel et al., 1968) . Whether the action of oestrogens in haemostasis is due to an effect on blood-clotting factors, on blood platelets, or on the blood vessel wall is not certain (Ulutin, 1969) .
The absence in this progesterone trial of rises in factors VII and X is in direct contrast to our results with all previous types of oral contraceptive. Even more encouraging, however, is the dramatic reduction seen in Fig. 1 of the raised levels of clotting-factors present in the women on conventional oestrogen-progesterone preparations when they change to progesterone alone.
Although factor X levels were considerably reduced after three months' progesterone administration in women who had taken conventional oestrogen-progesterone compounds previously, the level was still higher than normal. Further study will show whether factor X levels return to normal at a later date in this group.
An interesting additional feature is the reduction of dilute clot lysis time, suggesting an increase-in fibrinolytic activity in normal women during the first three months of taking chlormadinone.' This obviously needs more careful investigation and, if confirmed, suggests that progesterone may exert a protective influence against thrombosis. The absence of a rise in fibrinogen level with chlormadinone contrasts with our findings in a group on the combined preparations, Ortho-Novin and Norinyl-1, studied; in-parallel, though the latter had beeng The normal thromboelastographic pattern so far also contrasts with our findings during the administration of conventional preparations, as Fig. 2 shows. An extreme form of thromboelastographic hypercoagulability pattern in a patient who had been receiving an oestrogen-progestin compound and suffered a deep-vein thrombosis is illustrated for comparison. The absence so far of changes in platelet aggregation is likewise reassuring, as in parallel studies we have shown significant shortening of the platelet aggregation with the Chandler tube in women taking both high-dose and low-dose forms of combined preparations .
We should emphasize that these results, though extremely encouraging, reflect only the first three cycles of administration, and a long-term study must of course be performed to exclude a delayed or cumulative action. In so far as it is possible to be certain at this stage the investigation does suggest that the thrombogenic constituent of conventional oral contraception may have been eliminated by the use of progesterone alone.
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